JPH0584288B2 - - Google Patents
Info
- Publication number
- JPH0584288B2 JPH0584288B2 JP61109775A JP10977586A JPH0584288B2 JP H0584288 B2 JPH0584288 B2 JP H0584288B2 JP 61109775 A JP61109775 A JP 61109775A JP 10977586 A JP10977586 A JP 10977586A JP H0584288 B2 JPH0584288 B2 JP H0584288B2
- Authority
- JP
- Japan
- Prior art keywords
- drug
- lecithin
- bitter
- bitter taste
- drugs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 claims description 38
- 229940079593 drug Drugs 0.000 claims description 38
- 235000019658 bitter taste Nutrition 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 19
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 13
- 239000000787 lecithin Substances 0.000 claims description 13
- 235000010445 lecithin Nutrition 0.000 claims description 13
- 229940067606 lecithin Drugs 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical group [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 19
- 239000011248 coating agent Substances 0.000 description 15
- 239000000843 powder Substances 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 229940083466 soybean lecithin Drugs 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 238000000576 coating method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229960002780 talampicillin Drugs 0.000 description 6
- SOROUYSPFADXSN-SUWVAFIASA-N talampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(=O)OC2C3=CC=CC=C3C(=O)O2)(C)C)=CC=CC=C1 SOROUYSPFADXSN-SUWVAFIASA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 3
- 229960002695 phenobarbital Drugs 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010013911 Dysgeusia Diseases 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000008777 Glycerylphosphorylcholine Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- -1 Magnesium metasilicate aluminate Chemical class 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000002925 chemical effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000005496 eutectics Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- SUHOQUVVVLNYQR-MRVPVSSYSA-O glycerylphosphorylcholine Chemical compound C[N+](C)(C)CCO[P@](O)(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-O 0.000 description 1
- 229960004956 glycerylphosphorylcholine Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10977586A JPS62265234A (ja) | 1986-05-14 | 1986-05-14 | 苦味抑制製剤組成物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10977586A JPS62265234A (ja) | 1986-05-14 | 1986-05-14 | 苦味抑制製剤組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62265234A JPS62265234A (ja) | 1987-11-18 |
| JPH0584288B2 true JPH0584288B2 (xx) | 1993-12-01 |
Family
ID=14518910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10977586A Granted JPS62265234A (ja) | 1986-05-14 | 1986-05-14 | 苦味抑制製剤組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS62265234A (xx) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5407921A (en) * | 1993-07-01 | 1995-04-18 | Kao Corporation | Method for suppressing bitter taste |
| GB9702799D0 (en) * | 1997-02-12 | 1997-04-02 | Scherer Corp R P | Process for preparing solid pharmaceutical dosage forms |
| JP2001226293A (ja) * | 2000-02-17 | 2001-08-21 | Kotaro Kanpo Seiyaku Kk | 服用補助剤 |
| EP1476137A1 (en) * | 2002-01-28 | 2004-11-17 | Phares Pharmaceutical Research N.V. | Composition comprising low water soluble compounds within porous carriers |
| JP4808392B2 (ja) * | 2003-09-04 | 2011-11-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 苦味を隠蔽する薬理組成物 |
| JP4634886B2 (ja) * | 2005-08-03 | 2011-02-16 | 金秀バイオ株式会社 | 高機能性健康食品の苦味低減化方法、及び低苦味組成物 |
| JP5612909B2 (ja) * | 2010-05-31 | 2014-10-22 | テルモ株式会社 | 分岐鎖アミノ酸含有総合栄養食品 |
| CN106170213B (zh) * | 2014-04-10 | 2020-04-21 | 三得利控股株式会社 | 含有胶原蛋白肽组合物的苦味掩盖方法 |
| JP6549428B2 (ja) * | 2014-07-23 | 2019-07-24 | エスエス製薬株式会社 | 経口組成物 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS558966A (en) * | 1978-07-05 | 1980-01-22 | Euteco Spa | Tire |
| JPS60204739A (ja) * | 1984-03-28 | 1985-10-16 | Sekimoto Hiroshi | エイコサポリエン酸系化合物含有粉体 |
-
1986
- 1986-05-14 JP JP10977586A patent/JPS62265234A/ja active Granted
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS558966A (en) * | 1978-07-05 | 1980-01-22 | Euteco Spa | Tire |
| JPS60204739A (ja) * | 1984-03-28 | 1985-10-16 | Sekimoto Hiroshi | エイコサポリエン酸系化合物含有粉体 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS62265234A (ja) | 1987-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2126257C1 (ru) | Фармацевтическая композиция со сниженным горьким вкусом, содержащая азалид, и способ лечения бактериальной инфекции у млекопитающих (варианты) | |
| US6214386B1 (en) | Prompt-release oral pharmaceutical compositions for extemporaneous suspensions | |
| DK175329B1 (da) | Pulver med kontrolleret frigivelseshastighed, fremgangsmåde til fremstilling og anvendelse af dette | |
| KR0161969B1 (ko) | 실질적으로 수불용성인 약제학적 활성 성분을 위한 약제학적 수성 현탁액 조성물 | |
| KR0166064B1 (ko) | 회전 과립화 및 맛 은폐용 피막의 형성에 의한 저작성 약제학적 정제의 제조방법 | |
| KR950009090B1 (ko) | 수산화알루미늄을 함유하는 이부프로펜 조성물 | |
| RU2241460C2 (ru) | Фармацевтическая композиция цефуроксим аксетила с маскированным горьким вкусом | |
| JP3667778B2 (ja) | スフェロイド製剤 | |
| AU773555B2 (en) | Taste masked pharmaceutical liquid formulations | |
| BR112013009153B1 (pt) | Composição farmacêutica e uso da mesma | |
| EP2005945A2 (en) | Oseltamivir phosphate granule and preparation mehtod thereof | |
| KR19980070732A (ko) | 항균 활성 퀴놀론 유도체의 풍미 차폐성 제제의 제조방법 | |
| CN102151247A (zh) | 包含外消旋卡朵曲的干粉制剂 | |
| JPH0584288B2 (xx) | ||
| WO2004087111A1 (en) | Oral taste masked pharmaceutical compositions | |
| EP2538923A2 (en) | Taste-masked powder for suspension compositions of methylprednisolone | |
| US4832955A (en) | Controlled release potassium chloride composition | |
| JPH0296526A (ja) | 粉粒状医薬製剤 | |
| KR100395864B1 (ko) | 트리메부틴을함유하는신규제약조성물및그제조방법 | |
| JP4384278B2 (ja) | イブプロフェン含有粒剤 | |
| Madaan et al. | Taste Masking: Implemented Techniques With Patents | |
| JP2004075594A (ja) | 経口用ウコン類組成物 | |
| WO2000016742A1 (en) | Chewable compositions containing dextromethorphan | |
| WO2019043427A1 (en) | FAST SELF-DISPERSION DOSAGE FORMS OF DEFERASIROX | |
| JPS589083B2 (ja) | シヨウリユウザイノセイゾウホウ |